FDA Approves Talazoparib + Enzalutamide for HRR-Mutant Hormone-Sensitive Metastatic Prostate Cancer: TALAPRO-3

A PARP Inhibitor Moves Earlier in Prostate Cancer: What Do TALAPRO-3 and the FDA Decision Mean?

On October 26, 2026, the U.S. Food and Drug Administration (FDA) approved the PARP inhibitor talazoparib (Talzenna), in combination with enzalutamide, for metastatic prostate cancer that carries mutations in homologous recombination repair (HRR) genes and has not yet become resistant to hormone therapy (FDA announcement). With this decision, the combination moves from the castration-resistant stage, where it was previously approved, to an earlier stage of the disease. We have previously covered prostate cancer, castration-resistant prostate cancer, the approval of olaparib + abiraterone in BRCA-mutated prostate cancer and the molecular subtypes of prostate cancer.

Why does this matter?

About one in four metastatic prostate cancers carries a mutation in genes of the homologous recombination system, which repairs double-strand breaks in DNA (BRCA2, BRCA1, ATM, CDK12, CHEK2, PALB2 and others). A substantial share of these mutations are inherited and also concern family members (hereditary cancers and targeted drugs, ATM gene mutation). HRR-mutated tumors tend to behave more aggressively and to respond to standard hormone therapies for a shorter time.

PARP inhibitors exploit the repair defect of these tumors: in a cell where one repair pathway is already broken, they shut down the second pathway as well and stop the tumor cell from multiplying (this principle, called "synthetic vulnerability," is familiar from ovarian and breast cancer; PARP inhibitors in ovarian cancer). In prostate cancer, these drugs have so far been used mostly in the castration-resistant stage. The new approval means that HRR testing should now be done at diagnosis, in the hormone-sensitive stage.

Which patients is talazoparib + enzalutamide used for?

According to the FDA approval of October 26, 2026, talazoparib + enzalutamide is used in adults with metastatic prostate cancer that has mutations in homologous recombination repair (HRR) genes and has not yet been treated with androgen receptor pathway inhibitors or is still sensitive to them (hormone-sensitive). It is given in addition to androgen deprivation therapy (a GnRH analog or surgical castration; testosterone and prostate cancer). The mutation must be demonstrated in tumor tissue or blood with an FDA-approved test.

What did the TALAPRO-3 trial show?

TALAPRO-3 is a double-blind, randomized phase 3 trial in which 599 patients with HRR gene-mutated metastatic hormone-sensitive prostate cancer were assigned 1:1 to talazoparib + enzalutamide or placebo + enzalutamide. All patients received continuous androgen deprivation therapy. Of the patients, 84% were metastatic at diagnosis (de novo) and 70% had high-volume disease; about one-third had a BRCA1/2 mutation. Mutation status was determined by next-generation sequencing of tumor tissue or circulating tumor DNA in the blood. The results were presented at ASCO 2026 and published in the New England Journal of Medicine.

An HR below 1 favors talazoparib. Median follow-up was 37.6 months for radiographic progression-free survival and about 41 months for overall survival. After progression, 27% of patients in the placebo arm and 9% in the talazoparib arm later received olaparib.

Alongside the relative effect, the absolute difference is also meaningful: at 3 years, the proportion of patients living without radiographic progression rose by 20 percentage points in all patients and by 28 points in those with BRCA mutations. The overall survival difference at 3 years is 6 points; however, this difference is not yet statistically significant and will become clearer in the final analysis. The fact that some patients in the placebo arm later received a PARP inhibitor may narrow the survival difference. Trends in interim analyses should not be interpreted as definitive results (reading research correctly).

The approval was granted under Project Orbis, in which the FDA conducts concurrent reviews with the drug regulators of Australia and Canada; reviews in these countries are ongoing (the approval process for cancer drugs).

Side effects and warnings

Adding talazoparib clearly increased side effects. The most common problems were anemia, fatigue, low white blood cell (neutrophil) counts and weakness.

• Anemia: It occurred at any grade in 71% of patients and at grade 3–4 in 51%, appearing after a median of 3.2 months. Of those who developed anemia, 40% received a blood transfusion. With dose reduction, most patients were able to continue treatment; talazoparib was permanently discontinued because of anemia in only 5% of patients. Blood counts should be monitored closely during the first months of treatment.
• Bone marrow and leukemia risk: The prescribing information carries a warning for myelodysplastic syndrome and acute myeloid leukemia; in the trial, myelodysplastic syndrome occurred in 3 versus 1 patients and acute myeloid leukemia in 2 versus 0 patients.
• Other: There is a warning for embryo-fetal toxicity (patients whose partners could become pregnant need effective contraception). Loss of appetite was more pronounced in the talazoparib arm. The dose is reduced in patients with impaired kidney function (0.35 mg).

TALAPRO-3 and AMPLITUDE: two PARP combinations in the hormone-sensitive stage

The two trials have not been compared directly; patient populations, control treatments and follow-up times differ. HR values refer to radiographic progression-free survival.

The most important difference between the two combinations is seen in non-BRCA HRR mutations: in TALAPRO-3 there was a significant benefit in this group as well, whereas in AMPLITUDE the benefit was largely limited to BRCA2. Even so, the benefit very likely also differs among non-BRCA genes (for example, ATM or CHEK2); detailed analyses of these subgroups are awaited. The choice will be guided by the patient's risk of side effects (the need for steroids with abiraterone, and fatigue and fall risk with enzalutamide), heart and other conditions, and access.

Practical points for physicians

• Test early: At the diagnosis of metastatic hormone-sensitive prostate cancer, HRR testing now directly affects treatment choice. If tissue is insufficient, a blood-based (ctDNA) test is an option (comprehensive genomic tests, next-generation sequencing).
• Do not skip germline testing: If a BRCA or other HRR mutation is found on tumor testing, germline testing and genetic counseling should be offered; this finding matters for the risk of breast, ovarian, prostate and pancreatic cancer in the patient's daughters and sons (risk-reducing approaches in BRCA carriers).
• Be prepared for anemia: Take care in patients with anemia at baseline; plan frequent blood counts in the first months and early dose reduction if needed.
• No data after docetaxel: Patients who had received docetaxel in the hormone-sensitive stage were not enrolled in TALAPRO-3.
• Watch for resistance: Resistance to PARP inhibitors can develop over time; repeat genetic testing at progression may reveal the resistance mechanism (PARP inhibitor resistance).

Tips for patients and their families

• Learn the stage and risk group of your disease (prostate cancer risk classification).
• Ask for genetic testing: If you have been diagnosed with metastatic prostate cancer, ask whether HRR (especially BRCA) testing has been done on your tumor and your blood.
• Think of your family: If an inherited mutation is found, genetic counseling may be recommended for your family members.
• Report side effects: Symptoms such as fatigue, shortness of breath, paleness, easy bruising or fever may indicate that your blood counts have dropped; tell your doctor right away.
• Talk about your quality of life: Ask about the effects of hormone therapy on fatigue, hot flashes and sexual function, and how to manage them (life during treatment, sexual health, bone metastases).
• When making decisions, do not hesitate to get a second opinion.

Frequently asked questions

Who is talazoparib + enzalutamide approved for?

On October 26, 2026, the FDA approved this combination for adults with metastatic prostate cancer that has mutations in HRR genes (BRCA1, BRCA2, ATM, CDK12, CHEK2, PALB2 and others) and has not yet become resistant to hormone therapy. It is given in addition to androgen deprivation therapy, and the mutation must be demonstrated with an FDA-approved test.

How much benefit did talazoparib provide in the TALAPRO-3 trial?

The risk of radiographic progression or loss of life was reduced by 52% (HR 0.48). At 3 years, the proportion of patients living without progression was 77% versus 56%. The benefit was more pronounced with BRCA1/2 mutations (HR 0.37). Overall survival data are not yet mature.

What is the most important side effect of talazoparib?

Anemia. Half of the patients developed severe (grade 3–4) anemia, and some needed blood transfusions; however, with dose reduction most patients were able to continue treatment. Low white blood cell counts, fatigue and, rarely, bone marrow disorders may also occur.

When should HRR testing be done in prostate cancer?

With the new approvals, it is recommended at the diagnosis of metastatic prostate cancer, in the hormone-sensitive stage. The test can be done on tumor tissue or blood; if a mutation is found in the tumor, germline testing and genetic counseling are also needed.

Glossary

Hormone-sensitive (castration-sensitive) prostate cancer

Prostate cancer that still responds to androgen deprivation therapy.

Castration-resistant prostate cancer

Prostate cancer that progresses even though testosterone is suppressed.

HRR genes

Genes involved in the homologous recombination system, which repairs double-strand breaks in DNA (such as BRCA1, BRCA2, ATM, CDK12 and PALB2).

PARP inhibitor

A class of drugs that blocks the PARP enzyme involved in DNA repair and is effective in tumors with a defective repair system.

Radiographic progression-free survival

The time that passes without the disease progressing on imaging and without loss of life.

Androgen receptor pathway inhibitor

Drugs that suppress the androgen pathway, such as enzalutamide, abiraterone, apalutamide and darolutamide.

Companion diagnostic

A test approved to select the patients who will benefit from a drug.